Sarepta Therapeutics (NASDAQ: SRPT) and Vertex Pharmaceuticals (NASDAQ: VRTX) have a lot in common: Both operate in the tricky biotech industry, and both seek to develop treatments primarily for rare diseases or, at least, for conditions with severe unmet needs.

However, there is one significant difference between the two. Vertex has a long track record of clinical and regulatory success in its core therapeutic area, which has allowed it to generate growing revenue, profits, and outsized returns for years.

If Sarepta Therapeutics can come close to matching the overall performance of its larger peer over the long run, that would make it an excellent stock to buy today. Does the mid-cap biotech have what it takes? Let's find out.

Continue reading

Source Fool.com